Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
Extracellular Acidic pH Inhibits Oligodendrocyte Precursor Viability, Migration, and Differentiation.
Rates of Adverse Events and Multiple Sclerosis Relapses Before and After Introduction of a Purported Generic Glatiramer Acetate in mexico: Results from a Large Patient Support Program in Mexico.
Pushing the boundaries of neuromyelitis optica: Does antibody make the disease?
Neuroinflammation preceding and accompanying primary central nervous system lymphoma: case study and literature review.
Frontrunners of T cell activation: Initial, localized Ca2+ signals mediated by NAADP and the type 1 ryanodine receptor.
Optic neuritis as an initial manifestation of human herpesvirus 6 reactivation after unrelated bone marrow transplantation.
Established and novel disease-modifying treatments in multiple sclerosis.
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
Coculture of Primary Motor Neurons and Schwann Cells as a Model for In Vitro Myelination.
Variability in the Cross-Sectional Area and Narrowing of the Internal Jugular Vein in Patients Without Multiple Sclerosis.
Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.
Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.
[The latest advance of correlation between autophagy and optic neuritis].
Type I IFN receptor controls activated TYK2 in the nucleus: Implications for EAE therapy.
Cerebrospinal fluid derived immunoglobulin G of different multiple sclerosis patients share mutated sequences in complementarity determining regions.
A case of tumor-like inflammatory demyelinating disease with progressive brain and spinal cord involvement.
Nudging Oligodendrocyte Intrinsic Signaling to Remyelinate and Repair: Estrogen Receptor Ligand Effects.
Risk of fractures in patients with multiple sclerosis: A population-based cohort study.
Early IFN-γ production together with decreased expression of TLR3 and TLR9 characterizes EAE development conditional on the presence of myelin.
The effect of plasma exchange on serum anti-JC virus antibodies.
Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs).
Objectively Measured Physical Activity Is Associated with Brain Volumetric Measurements in Multiple Sclerosis.
Novel molecular insights into classical and alternative activation states of microglia as revealed by SILAC-based proteomics.
Multiple sclerosis: getting personal with induced pluripotent stem cells.
Pages
« first
‹ previous
…
484
485
486
487
488
489
490
491
492
…
next ›
last »